

Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up

Rs. Mio.	Q2 12-13	Q2 11-12	% Gr y-y	YTD 12-13	YTD 11-12	% Gr y-y
Domestic	7,637	6,100	25.2%	15090	12046	25.3%
Formulations	6,018	4,700	28.0%	11,835	9,274	27.6%
API	116	68	70.6%	224	134	67.2%
Wellness	965	879	9.8%	1,998	1,793	11.5%
Animal Health & Others	538	453	18.8%	1,033	845	22.2%
Exports	6,510	5,539	17.5%	13,228	10,356	27.7%
Formulations	5,820	4,893	19.0%	11,772	9,029	30.4%
US	3,674	3,070	19.7%	7,266	5,463	33.0%
Europe	762	619	23.1%	1,617	1,388	16.5%
Japan	143	120	19.3%	282	232	21.6%
Brazil	487	655	-25.7%	1,131	1,125	0.5%
Emerging Mkts & Others	754	429	76.0%	1,476	821	79.8%
API	588	563	4.6%	1,238	1,243	-0.4%
Animal Health & Others	102	84	21.2%	218	84	159.6%
JVs	1,300	750	73.4%	2,595	1,876	38.3%
Total	15,447	12,389	24.7%	30,913	24,278	27.3%

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q2 12-13	Q2 11-12	% Gr y-y	YTD 12- 13	YTD 11- 12	% Gr y-y
Other Operating Income	351	168	109.6%	1,135	889	27.6%
Dossier Fees	2	62	-96.8%	2	493	-99.6%
Royalty Income	140	54	159.3%	296	106	179.2%
Net Gain on foreign currency transactions and translation (Refer Note below)	17	-92	118.8%	476	0	
Others	192	144	33.7%	361	290	24.5%

Note : Apart from this gain, there was a loss of Rs. 641 Mio. in Q2 12-13 on hedging and on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods. Thus, on aggregate level, there was a loss of Rs. 624 Mio. on operating transactions (above EBIDTA line) in Q2 12-13 vs loss of Rs. 206 Mio. in Q2 11-12. See details below for more clarity.

Rs. Mio.	Q2 12-13	Q2 11-12	% Gr y-y	YTD 12- 13	YTD 11- 12	% Gr y-y
Other Income	65	110	-40.4%	160	174	-8.1%
Interest & Dividend income	72	104	-30.8%	140	143	-2.4%
Profit on sale of investments	4	4	8.9%	6	5	12.3%
Profit on sale of assets	-9	-9	3.8%	0	12	-100.0%
Others	-2	11	-118.2%	14	14	1.9%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q2 12-13	Q2 11-12	% Gr y-y	YTD 12- 13	YTD 11- 12	% Gr y-y
A. On operating transactions (above EBIDTA line)	624	206	202.5%	184	76	141.4%
a. Included in other income	-17	92	-118.8%	-476	0	
b. Included in cost of goods	641	-180	456.3%	660	-218	402.7%
c. Included in other expenses		294	-100.0%		294	-100.0%
B. On Foreign Currency Borrowings (part of interest cost)	133	514	-74.2%	404	451	-10.5%
Total Foreign Currency Fluctuations (+ = loss, - = gain)	757	720	5.1%	588	527	11.5%

Details of R&D Expenses

Rs. Mio.	Q2 12-13	Q2 11-12	% Gr y-y	YTD 12- 13	YTD 11- 12	% Gr y-y
Total R&D Expenses	1,172	847	38%	2,044	1,602	28%

Consolidated Capex for Apr-Sep 12

**Rs. 3957
Mio.**

R&D capex included in above for Apr-Sep 12 :

**Rs. 349
Mio.**